Charles S. Fuchs, MD, MPH is the Director of the Yale Cancer Center (YCC), an NCI-Designated Comprehensive Cancer Center, and Physician-in-Chief of Smilow Cancer Hospital, assuming those roles in January 2017. Dr. Fuchs has spent his career leading research programs in gastrointestinal cancer epidemiology, biology, and drug development, while caring for patients with these malignancies as a practicing medical oncologist.
Prior to joining Yale, Dr. Fuchs served as Robert T. and Judith B. Hale Chair in Pancreatic Cancer Dana-Farber Cancer Institute and Harvard Medical School and Chief of the Gastrointestinal Oncology Division. He successfully launched the Dana-Farber/Harvard SPORE Grant in GI Cancer, as its first Director, and was the Founding Director of the Hale Family Center for Pancreatic Cancer.
As Yale Cancer Center Director, Dr. Fuchs leads >450 clinicians and scientists, dedicated to advancing high-impact science and clinical innovation. Under Dr. Fuchs’ leadership, YCC launched new scientific initiatives, including the Yale Center for Immuno-Oncology, the Program in Cellular Therapy, the Center for Molecular and Cellular Oncology, and the Bridge Center for Community Engagement and Health Equity, while expanding clinical, translational, population, and basic science programs and funding. On the basis of these and other accomplishments, YCC recently enjoyed a successful renewal of NCI-designation, resulting in a 73% increase in CCSG funding.
As Physician-in-Chief of Smilow Cancer Hospital, Dr. Fuchs oversees a growing clinical enterprise, which includes a 15-story dedicated clinical building in New Haven and 16 fully integrated Smilow Cancer Hospital Care Centers across Connecticut and Rhode Island. In 2019, Smilow Cancer Hospital provided care to 48% of all newly diagnosed cancer patients in the state of Connecticut.
Dr. Fuchs’ own research has benefitted from continuous NIH funding since 1993 and includes work in molecular epidemiology, tumor biology, and drug development, with over 600 publications. He has built teams of scientists, epidemiologists, and young investigators to rigorously define risk factors for major cancers and overall mortality through large prospective cohort studies that have informed cancer prevention. He established a large-scale molecular epidemiology laboratory for biospecimens from prospective cohort studies of >300,000 participants, conducting whole exome sequencing, gene expression analyses, and metabolomic analyses that have been providing insight into cancer biology, prevention, and treatment. Dr. Fuchs created the first North American prospective cohort studies of cancer patients to assess the impact of diet and lifestyle on cancer survival, and he has translated his research findings into clinical trials in cancer prevention and treatment. Finally, Dr. Fuchs is an internationally recognized expert in gastrointestinal oncology and has led pivotal clinical trials assessing novel targeted therapies that have ultimately resulted in FDA approval of new agents for cancer therapy.
Dr. Fuchs currently serves as a member of the External Advisory Board for the Mayo Clinic and Herbert Irving (Columbia) Cancer Centers, the Scientific Advisory Board for the Lustgarten Foundation for Pancreatic Cancer Research, and the Finance Committee for the American Association for Cancer Research. He was a member of the National Cancer Institute Blue Ribbon Panel Working Group. He also co-founded Evolveimmune Therapeutics, a biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases.
Dr. Fuchs received his BA in Biochemistry from the University of Pennsylvania, his MD from Harvard Medical School, his MPH from the Harvard School of Public Health, and an MA (Hon) from Yale University. He was elected to the Association of American Physicians (2014) and was the recipient of the Eugene O’Kelley Humanitarian Award (2016) and the Giants of Cancer Care Award (2017).